-
2024-511166-36-00
5
2025-06-13
Moderate to Severe Plaque Psoriasis
-
2024-517819-74-00
9
2025-06-02
Pancreatic Ductal Adenocarcinoma
-
2023-504478-39-00
5
2025-05-23
Squamous cell carcinoma of head and neck
-
2024-518475-58-00
6
2025-05-15
Septic shock, acute kidney injury
-
2023-507936-20-00
5
2025-05-05
Acute myeloid leukemia
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2024-512484-31-00
4
2025-02-28
FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2023-507746-83-00
5
2024-11-27
Generalized Myasthenia Gravis
-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
-
2023-505606-42-00
5
2024-10-15
Head and Neck Squamous Cell Carcinoma (HNSCC)
-
2022-502825-17-00
4
2024-10-07
Melanoma
-
2023-507536-21-00
7
2024-10-04
Advanced Solid Tumors
-
2023-510017-26-00
1
2024-10-02
Completely Resected Stage IIB, IIC, and III Melanoma
-
2023-510022-33-00
5
2024-10-02
HIV-1 infection
-
2023-506227-29-00
3
2024-08-30
locally advanced or metastatic solid tumors
-
2023-509606-30-00
5
2024-07-24
Ulcerative colitis
-
2022-501105-12-00
5
2024-07-15
Urothelial Carcinoma
-
2023-508099-12-00
5
2024-06-20
Dermatitis atopic
-
2022-500030-28-01
4
2024-06-10
Urothelial carcinoma
-
2023-503221-19-00
4
2024-04-18
Advanced Non-Small Cell Lung Cancer
-
2023-507039-39-00
5
2024-03-22
Moderate to Severe Plaque Psoriasis
-
2022-502660-20-00
5
2024-01-23
Follicular lymphoma